Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

Regina García-Delgado; Dunia de Miguel; Alicia Bailén; José Ramón González; Joan Bargay; José F. Falantes; Rafael Andreu; Fernando Ramos; Mar Tormo; Salut Brunet; Antonio Figueredo; Javier Casaño; Ángeles Medina; Llorenç Badiella; Antonio Fernández Jurado; Guillermo Sanz

doi:10.1016/j.leukres.2014.03.004

Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

Regina García-Delgado, Dunia de Miguel, Alicia Bailén, José Ramón González, Joan Bargay, José F. Falantes, Rafael Andreu, Fernando Ramos, Mar Tormo, Salut Brunet, Antonio Figueredo, Javier Casaño, Ángeles Medina, Llorenç Badiella, Antonio Fernández Jurado, Guillermo Sanz

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

36 Citations (Scopus)

Abstract

We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules. © 2014 The Authors.

Original language	English
Pages (from-to)	744-750
Journal	Leukemia Research
Volume	38
Issue number	7
DOIs	https://doi.org/10.1016/j.leukres.2014.03.004
Publication status	Published - 1 Jan 2014

Keywords

Acute myeloid leukemia
Azacitidine
Dosing schedules
Myelodysplastic syndromes
Overall survival
Safety

Access to Document

10.1016/j.leukres.2014.03.004

Cite this

García-Delgado, R., de Miguel, D., Bailén, A., González, J. R., Bargay, J., Falantes, J. F., Andreu, R., Ramos, F., Tormo, M., Brunet, S., Figueredo, A., Casaño, J., Medina, Á., Badiella, L., Jurado, A. F., & Sanz, G. (2014). Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Leukemia Research, 38(7), 744-750. https://doi.org/10.1016/j.leukres.2014.03.004

@article{e49799a663cc4204a685749d030771d3,

title = "Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia",

abstract = "We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules. {\textcopyright} 2014 The Authors.",

keywords = "Acute myeloid leukemia, Azacitidine, Dosing schedules, Myelodysplastic syndromes, Overall survival, Safety",

author = "Regina Garc{\'i}a-Delgado and {de Miguel}, Dunia and Alicia Bail{\'e}n and Gonz{\'a}lez, {Jos{\'e} Ram{\'o}n} and Joan Bargay and Falantes, {Jos{\'e} F.} and Rafael Andreu and Fernando Ramos and Mar Tormo and Salut Brunet and Antonio Figueredo and Javier Casa{\~n}o and {\'A}ngeles Medina and Lloren{\c c} Badiella and Jurado, {Antonio Fern{\'a}ndez} and Guillermo Sanz",

year = "2014",

month = jan,

day = "1",

doi = "10.1016/j.leukres.2014.03.004",

language = "English",

volume = "38",

pages = "744--750",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "7",

}

García-Delgado, R, de Miguel, D, Bailén, A, González, JR, Bargay, J, Falantes, JF, Andreu, R, Ramos, F, Tormo, M, Brunet, S, Figueredo, A, Casaño, J, Medina, Á, Badiella, L, Jurado, AF & Sanz, G 2014, 'Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia', Leukemia Research, vol. 38, no. 7, pp. 744-750. https://doi.org/10.1016/j.leukres.2014.03.004

TY - JOUR

T1 - Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

AU - García-Delgado, Regina

AU - de Miguel, Dunia

AU - Bailén, Alicia

AU - González, José Ramón

AU - Bargay, Joan

AU - Falantes, José F.

AU - Andreu, Rafael

AU - Ramos, Fernando

AU - Tormo, Mar

AU - Brunet, Salut

AU - Figueredo, Antonio

AU - Casaño, Javier

AU - Medina, Ángeles

AU - Badiella, Llorenç

AU - Jurado, Antonio Fernández

AU - Sanz, Guillermo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules. © 2014 The Authors.

AB - We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules. © 2014 The Authors.

KW - Acute myeloid leukemia

KW - Azacitidine

KW - Dosing schedules

KW - Myelodysplastic syndromes

KW - Overall survival

KW - Safety

U2 - 10.1016/j.leukres.2014.03.004

DO - 10.1016/j.leukres.2014.03.004

M3 - Article

VL - 38

SP - 744

EP - 750

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 7

ER -

Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

Abstract

Keywords

Access to Document

Fingerprint

Cite this